Table 1 Patient characteristics of the unadjusted and IPTW-weighted TuPro and control cohorts

From: Comparative cost analysis of a diagnostic multi-omics platform for decision support in advanced cancer – results from the Tumor Profiler Melanoma project

 

Unadjusted

IPTW weighted

Non-TuPro

TuPro

SMD

Non-TuPro

TuPro

SMD

(N = 124)

(N = 89)

 

(N = 94.3)

(N = 83.3)

Age (y)

65.9 (53.7–73.5)

61.0 (52.0–73.0)

0.115

64.6 (53.7–73.4)

65.4 (53.0–75.0)

0.087

Age group

  

0.159

  

0.056

 80+ years

14 (11.3%)

6 (6.7%)

 

11.1 (11.8%)

11.4 (13.7%)

 

 Gender

  

0.205

  

0.479

 Female

42 (33.9%)

39 (43.8%)

 

29.6 (31.4%)

45.3 (54.4%)

 

Stage

  

0.683

  

0.539

 Stage I

1 (0.8%)

0 (0.0%)

 

0.0 (0.0%)

0.0 (0.0%)

 

 Stage II

2 (1.6%)

0 (0.0%)

 

1.2 (1.3%)

0.0 (0.0%)

 

 Stage III

68 (54.8%)

23 (26.1%)

 

40.9 (43.4%)

17.3 (20.8%)

 

 Stage IV

53 (42.7%)

65 (73.9%)

 

52.1 (55.3%)

65.9 (79.2%)

 

 Missing

0 (0%)

1 (1.1%)

    

ECOG

  

0.267

  

0.378

 0

89 (76.7%)

71 (80.7%)

 

69.2 (73.4%)

67.8 (81.5%)

 

 1

22 (19.0%)

14 (15.9%)

 

21.1 (22.4%)

11.2 (13.5%)

 

 2

2 (1.7%)

3 (3.4%)

 

1.6 (1.7%)

4.2 (5.1%)

 

 3

3 (2.6%)

0 (0.0%)

 

2.4 (2.6%)

0.0 (0.0%)

 

Missing

8 (6.5%)

1 (1.1%)

    

Charlson Comorbidity Index

8.0 (7.0–9.0)

7.0 (6.0–9.0)

0.521

8.0 (7.0–9.0%)

8.0 (7.0–9.0%)

0.045

 Missing

0 (0%)

1 (1.1%)

 

NA

NA

 

Brain metastasis

  

0.006

  

0.182

 Yes

24 (19.4%)

17 (19.1%)

 

23.1 (24.5%)

27.2 (32.7%)

 

Location of primary

  

0.073

  

0.159

 Skin

97 (78.2%)

69 (78.4%)

 

69.2 (73.4%)

66.0 (79.2%)

 

 Mucosal

6 (4.8%)

4 (4.5%)

 

3.3 (3.5%)

2.0 (2.4%)

 

 Uveal

8 (6.5%)

7 (8.0%)

 

8.0 (8.5%)

4.4 (5.3%)

 

 Unknown

13 (10.5%)

8 (9.1%)

 

13.7 (14.6%)

10.9 (13.0%)

 

 Missing

0 (0%)

1 (1.1%)

    

Intention of treatment

  

1.123

  

0.557

 Adjuvant

65 (52.4%)

13 (14.6%)

 

37.0 (39.2%)

16.0 (19.2%)

 

 Palliative - SOC

56 (45.2%)

47 (52.8%)

 

53.4 (56.7%)

54.0 (64.8%)

 

 Palliative - beyond SOC

3 (2.4%)

29 (32.6%)

 

3.9 (4.1%)

13.3 (15.9%)

 

Treatment Line

  

1.471

  

0.583

 0 (adjuvant)

65 (52.4%)

13 (14.6%)

 

37.0 (39.2%)

16.0 (19.2%)

 

 1

49 (39.5%)

20 (22.5%)

 

37.4 (39.7%)

39.0 (46.8%)

 

 2

8 (6.5%)

24 (27.0%)

 

14.9 (15.8%)

14.4 (17.3%)

 

 3

0 (0.0%)

13 (14.6%)

 

0.0 (0.0%)

%

 

 4+

2 (1.6%)

19 (21.3%)

 

5.0 (5.3%)

8.3 (9.9%)

 

BRAF V600E Status

  

0.145

  

0.004

Non-Mutated

69 (56.1%)

43 (48.9%)

 

50.5 (54.0%)

44.8 (53.8%)

 

Mutated

54 (43.9%)

45 (51.1%)

 

43.1 (46%)

38.5 (46.2%)

 

Missing

1 (0.8%)

1 (1.1%)

    
  1. SMD standardized mean difference, SOC standard of care, y years, TuPro Tumor Profiler project melanoma cohort, synchronous Non-TuPro control cohort. N = refers to the number of treatment lines in the TuPro and Non-TuPro cohorts, respectively. All results are depicted as either median (interquartile range) or N (% of total). If multiple treatment lines were reported in a cohort, the patient characteristics at the first reported treatment line are rendered.
Back to article page